Clinical Scorecard: Erratum: Comparison of Axillary Surgery and Non-Axillary Staging in T1N0 Breast Cancer: Two-Decade Follow-Up of the INT 09/98 Randomized Clinical Trial

At a Glance

Key Highlights

• Axillary surgery now primarily serves as a staging method for guiding adjuvant therapies.
• High incidence of distant metastases in patients with axillary recurrence may indicate aggressive tumor biology.
• Similar rates of axillary relapse with distant metastases were observed in patients with positive nodes at primary surgery.

Guideline-Based Recommendations

Diagnosis

• Utilize sentinel lymph node biopsy for axillary staging in T1N0 breast cancer.

Management

• Consider the biological aggressiveness of tumors when evaluating axillary recurrence and distant metastases.
• Recognize that axillary surgery's role is primarily for staging rather than therapeutic benefit.

Monitoring & Follow-up

• Monitor patients with axillary recurrence closely for distant metastases due to potential aggressive tumor biology.

Risks

• Axillary recurrence with distant metastases may indicate a biologically aggressive subgroup with poorer prognosis.

Patient & Prescribing Data

Patients with T1N0 breast cancer undergoing axillary staging

Patients with axillary recurrence or involvement at baseline who develop distant metastases may have genomically determined poorer prognosis, independent of surgical or adjuvant treatments.

Clinical Best Practices

• Adopt sentinel lymph node biopsy as standard for axillary staging in early breast cancer.
• Interpret axillary recurrence and distant metastases as potential markers of aggressive tumor biology.
• Tailor adjuvant therapy decisions based on staging results and tumor biology rather than surgical extent alone.

References

• Original Article: Axillary surgery versus no-axillary staging in T1N0 breast cancer: 20-year follow-up of the INT 09/98 randomized clinical trial